Ntp Radioisotopes

What Ntp Radioisotopes does

NTP Radioisotopes SOC Ltd is a South African state-owned producer and global supplier of medical radioisotopes and radiation-based products, operating as a wholly-owned subsidiary of the South African Nuclear Energy Corporation (Necsa) under the Department of Energy. The company is headquartered at the Pelindaba nuclear facility near Pretoria and was formally incorporated in October 2003, though its operational roots extend to 1965 when the SAFARI-1 research reactor first achieved criticality. NTP supplies approximately 25-30% of global molybdenum-99 demand and exports radiopharmaceutical and radiochemical products to 50 countries, with products used in 8-10 million diagnostic imaging procedures annually.

The company's core technology is the SAFARI-1 20MW pool-type research reactor, which produces medical radioisotopes through neutron bombardment of enriched uranium targets, complemented by an on-site cyclotron facility for accelerator-based isotope production including F-18 FDG. NTP's product portfolio spans bulk radiochemicals (molybdenum-99, iodine-131), finished radiopharmaceuticals (NovaTec-P Tc-99m generators, Gluscan FDG, labelling kits including RENATEK, MDP, DISIDA), and industrial radioactive sources (iridium-192, cobalt-60, caesium-137). The company was the first commercial producer of all-LEU (low-enriched uranium) molybdenum-99, achieving FDA approval in 2010. Five operating subsidiaries support the integrated value chain: AEC-Amersham (sub-Saharan distribution), NTP Logistics (51%-owned hazardous goods transport JV), Gammatec NDT Supplies (industrial sources, 70+ countries), and Gamwave Gauteng (gamma sterilization).

NTP operates a B2B enterprise sales model through direct relationships with major global radiopharmaceutical and medical imaging companies, with 24/7 production operations to serve time-sensitive short-half-life isotope demand. Revenue streams include bulk medical radioisotope sales, finished radiopharmaceutical products, specialized freight and logistics services, industrial sealed sources, and neutron irradiation services such as silicon doping. The company holds FDA, EU cGMP, ISO 9001:2015, and South African National Nuclear Regulator certifications, and generates annual turnover exceeding R1.2 billion from a workforce of over 400 employees across the integrated Pelindaba operations and five subsidiaries.

Name

Ntp Radioisotopes

Legal name

NTP Radioisotopes SOC Ltd

Website

https://ntp.co.za

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

NTP Radioisotopes SOC Ltd is a South African state-owned producer of medical radioisotopes, supplying approximately 25-30% of global molybdenum-99 demand from its SAFARI-1 research reactor at Pelindaba to radiopharmaceutical companies and nuclear medicine providers across 50 countries.

Ownership category

akta.pro rank

Product category

Medical Radioisotopes and Radiopharmaceuticals

NAICS

Medical Equipment and Supplies Manufacturing (3391), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industries

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Industrial Isotope Production & Supply (Co-60, Ir-192, Cs-137, Am-241, etc.) (EUAKAIAB), Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH)

Keywords

• Medical radioisotope production
• Radiopharmaceutical manufacturing
• Molybdenum-99 supply
• Nuclear medicine products
• Industrial radioactive sources

Headquarters

HQ city

Brits

HQ country

South Africa

HQ region

Africa

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Infrastructure, Personnel, Technology or R&D, Supply Chain, Operations

Revenue model

1. Medical Radioisotope Sales: Production and sale of bulk medical radiochemicals including molybdenum-99, iodine-131, and technetium-99m generators. These short-lived radioisotopes cannot be stockpiled and require daily production and rapid delivery to customers.
2. Radiopharmaceutical Products: Sale of finished radiopharmaceutical products including NovaTec-P Tc-99m generators, labelling kits, iodine-131 capsules, Gluscan FDG, and patient-ready doses. Supply to nuclear medicine community.
3. Freight and Logistics Services: NTP Logistics (51% owned subsidiary) provides global distribution of hazardous goods and time-sensitive products with specialized transport containers and regulatory compliance.
4. Industrial Radioactive Sources: Production and sale of sealed radioactive sources including iridium-192 for non-destructive testing, cobalt-60, and caesium-137 for industrial radiography and process control.
5. Irradiation Services: Neutron transmutation doping of silicon crystals and other neutron irradiation services using SAFARI-1 reactor.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

NTP Radioisotopes SOC Ltd produces, processes, and globally supplies medical radioisotopes and radiopharmaceuticals using the SAFARI-1 nuclear research reactor and on-site cyclotron facilities at the Pelindaba nuclear site near Pretoria, South Africa. Its portfolio includes Molybdenum-99, Iodine-131, Technetium-99m (via the proprietary NovaTec-P generator), Gluscan FDG for PET imaging, radiopharmaceutical labelling kits, and industrial radioactive sources such as Iridium-192. Products are sold to nuclear medicine providers and radiopharmaceutical companies in 50 countries for diagnostic imaging and therapeutic applications.

Product overview

NTP Radioisotopes SOC Ltd is a state-owned South African company and subsidiary of Necsa offering an integrated production, processing, and distribution service for radiation-based products. The core portfolio centers on medical radioisotopes, with Molybdenum-99 (Mo-99) as the flagship product supplying up to a third of global demand. The product line includes parent isotopes (Mo-99, Iodine-131), daughter isotopes (Technetium-99m via NovaTec-P generators), finished radiopharmaceuticals (Gluscan FDG, labelling kits), and industrial radioactive sources (Iridium-192, Cobalt-60, Caesium-137). The integrated offering spans from target irradiation in the SAFARI-1 reactor through radiochemical processing to final product delivery via NTP Logistics.

Differentiator

Problem solved

Functional benefit

Brands

• Gluscan® FDG: F-18 fluorodeoxyglucose radiopharmaceutical for PET imaging used in diagnosis and staging of cancers, cardiac and neurological disorders.
• NovaTec-P Tc-99m Generator
• Ir-192 Sources

Products and services

• Molybdenum-99 (Mo-99) The world's most important medical diagnostic radioisotope precursor and parent isotope of technetium-99m (Tc-99m). Produced through neutron bombardment of enriched uranium-235 targets in the SAFARI-1 reactor. Sold in bulk to radiopharmaceutical companies globally; supplies approximately 30% of world Mo-99 demand.
• Iodine-131 (I-131) Radioactive isotope of iodine used in nuclear medicine procedures to diagnose and treat conditions of the thyroid, including hyperthyroidism and thyroid cancer. Sold as capsules and bulk radiochemical to nuclear medicine providers worldwide.
• Technetium-99m (Tc-99m) Primary radioisotope used in nuclear medicine diagnostic procedures, emitting gamma rays detectable by gamma cameras for imaging internal biological processes. Used in more than 40 million diagnostic procedures globally each year. Delivered via the NovaTec-P generator or as bulk Tc-99m.
• NovaTec-P Tc-99m Generator Proprietary dry-shipped Tc-99m generator developed by NTP Radioisotopes. Compact unit with two-vial system offering high-yield, pyrogen-free sterile eluate containing sodium pertechnetate for intravenous administration. Contains Mo-99 feedstock produced on-site at Pelindaba. Integrated radiation shielding enables use by hospitals and nuclear medicine centers.
• Radiopharmaceutical Labelling Kits Specialist labelling kits used in nuclear medicine procedures, including MDP (skeletal system), RENATEK (kidneys), DISIDA (hepatobiliary system), TIN COLLOID (liver function), and RBC (red blood cells). For use by nuclear medicine providers.
• Gluscan FDG F-18 fluorodeoxyglucose (FDG) radiopharmaceutical for PET and PET-CT medical imaging, used for diagnosis and staging of cancers and assessment of cardiac and neurological disorders. Produced on-site using a 16MeV GE PetTrace cyclotron with integrated production, QC, dispensing, and dispatch systems.
• Iridium-192 (Ir-192) Sealed Sources High-purity (>99.9%) activated iridium-192 sealed sources for non-destructive testing gamma radiography and industrial applications. Supplied in standard activity strengths from 30 Ci to 120 Ci. For industrial NDT operators and radiography service companies.
• Radioactive Sealed Sources Bulk radioactive sealed sources including cobalt-60 and caesium-137 for non-destructive testing, process control measurements, level/density control, flow rate measurement, belt weighing, and static elimination. For industrial customers.
• Neutron Irradiation Services Neutron transmutation doping of silicon crystals and other neutron irradiation services using the SAFARI-1 reactor. For semiconductor and industrial customers requiring high-flux neutron sources.
• Radioactive Material Logistics Services Global distribution of hazardous goods and time-sensitive radioactive products with specialized transport containers, licensed fleet for radioactive material transport, and full regulatory compliance. Provided by NTP Logistics SOC Ltd (51% owned subsidiary).

Quantifiable outcome

• SAFARI-1 produces approximately 30% of global molybdenum-99 demand
• +3 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core, minor and regional.

• ICPO FoundationcoreStrategic or Co-development Partner · 4 September 2023Strategic partnership to promote international education standards and support the establishment of new theranostics centers across Africa. The partnership aims to advance nuclear medicine education and expand access to theranostic treatments on the African continent.
• Cricket South Africa (CSA)minorGTM or Marketing Partner · 30 March 2023Sports sponsorship partnership announced in March 2023 for marketing and brand visibility purposes.
• ANSTO (Australian Nuclear Science and Technology Organisation)coreStrategic or Co-development Partner · 1 January 2012Partnership since 2012 for construction of a large-scale Mo-99 production facility using NTP's expertise and technology at ANSTO's Lucas Heights facility near Sydney, Australia. Will ensure uninterrupted Mo-99 supply after planned closures of facilities in Canada and Europe.
• IRE (Belgium)coreStrategic or Co-development Partner · 1 January 2009Nearly two decades of consortium supply arrangement with IRE of Belgium. Each organization provides back-up Mo-99 supply for the other during maintenance periods or disruptions. This partnership contributed to NTP's status as a world-leading Mo-99 supplier.
• iThemba LABSregionalTechnology or IntegrationPartnership with National Research Foundation's iThemba LABS near Cape Town for cyclotron facility providing accelerator-produced radioactive isotopes for nuclear medicine and research purposes in the Western Cape.
• OECD Nuclear Energy Agency HLG-MRcoreStrategic or Co-development PartnerNTP is a member of the OECD Nuclear Energy Agency High-level Group on the Security of Supply of Medical Radioisotopes. In June 2016, NTP Group MD Tina Eboka was elected Vice Chair.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Curium Pharma: Global nuclear medicine company producing Mo-99, Tc-99m generators, I-131 and other radiopharmaceuticals. Directly comparable to NTP as a vertically-integrated medical isotope producer and radiopharmaceutical manufacturer serving global nuclear medicine customers.
• GE HealthCare (Radiopharma): Major customer of NTP's Mo-99/I-131 and also one of the largest global radiopharmaceutical and PET tracer producers (via its former GE Healthcare division). Competes in finished radiopharmaceutical distribution while sourcing bulk isotopes from suppliers like NTP.
• Lantheus Holdings: Leading radiopharmaceutical-focused company (DEFINE, NEUROLITE, TechneLite generators). Sources Mo-99 from NTP and others, including NorthStar, and competes in finished radiopharmaceuticals — directly comparable to NTP's downstream businesses.
• Eczacıbaşı-Monrol: Turkish radiopharmaceutical producer covering Europe, Middle East and Africa with Mo-99-derived Tc-99m generators, I-131, Lu-177, and other isotopes. Comparable to NTP as a regional radiopharmaceutical manufacturer also serving African and emerging markets.
• HTA Co. Ltd (China Isotope & Radiation Corporation subsidiary): Chinese reactor-based and cyclotron-based radioisotope producer for medical and industrial use; serves as both customer and competitor of NTP, especially in Asian markets. Directly comparable bulk isotope product line.
• IRE (Institut National des Radioéléments): Belgian producer of Mo-99 and other radioisotopes; NTP's long-standing consortium partner providing mutual backup supply. Operates the BR2 reactor-based production — directly comparable medical isotope producer facing similar reactor-based economics.
• ANSTO (Australian Nuclear Science and Technology Organisation): Australian state entity operating the OPAL reactor for Mo-99 production; technology partner with NTP for a new large-scale Mo-99 facility. Directly comparable as a national-lab-backed, reactor-based medical isotope producer in the southern hemisphere.
• Curium/Mallinckrodt Nuclear Medicine: Following the 2023 acquisition of Mallinckrodt's nuclear imaging business by Curium, the entity operates as one of the largest global radiopharmaceutical manufacturers with comparable bulk Mo-99/Tc-99m supply and downstream kit/generator products.
• Jubilant DraxImage (Jubilant Pharma): Canadian/Indian radiopharmaceutical manufacturer producing I-131, Mo-99/Tc-99m generators, and branded radiopharmaceutical kits. Both customer and competitor of NTP in the medical isotope value chain.

Regional players

• Nihon Medi-Physics: Japanese radiopharmaceutical joint venture (GE HealthCare and Sumitomo) producing SPECT/PET imaging agents and bulk isotopes for Japan. Comparable product portfolio to NTP but operating primarily in Japan rather than competing globally head-to-head.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ntp Radioisotopes